KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) Other Gross PP&E Adjustments (2017 - 2025)

Amneal Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 9 years, most recently at $988.4 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $988.4 million for Q4 2025, up 6.43% from a year ago — trailing twelve months through Dec 2025 was $988.4 million (up 6.43% YoY), and the annual figure for FY2025 was $988.4 million, up 6.43%.
  • Other Gross PP&E Adjustments for Q4 2025 was $988.4 million at Amneal Pharmaceuticals, up from -$31.8 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for AMRX hit a ceiling of $988.4 million in Q4 2025 and a floor of -$192.6 million in Q1 2021.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$78.1 million (2023), compared with a mean of $148.0 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: crashed 43.65% in 2022 and later skyrocketed 93.15% in 2025.
  • Amneal Pharmaceuticals' Other Gross PP&E Adjustments stood at $842.8 million in 2021, then grew by 1.32% to $853.9 million in 2022, then increased by 5.12% to $897.6 million in 2023, then rose by 3.46% to $928.7 million in 2024, then increased by 6.43% to $988.4 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $988.4 million (Q4 2025), -$31.8 million (Q3 2025), and -$17.7 million (Q2 2025) per Business Quant data.